Loading
A protein normally only in testis that some sarcomas and other tumours switch on; T cells can be engineered to recognise fragments of it. This dossier gathers the 1 product (1 approved), 2 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Intracellular; presented as peptide-HLA complex.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Sarcomas | 60-80% | Synovial sarcoma, IHC/RNA | HLA-A*02 needed for TCR-T; ~40-45% of population | Wikipedia |
| Non-small-cell lung cancer | 20-30% | Squamous enriched | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved |
|---|---|
| Cell therapy 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 2 | Active | A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | - | ||
SPEARHEAD-3 Pediatric Study NCT05642455 | 1/2 | Recruiting | A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"MAGE-A4" OR ABSTRACT:"MAGE-A4" OR TITLE:"MAGEA4" OR ABSTRACT:"MAGEA4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MAGE-A4, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/mage-a4.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/mage-a4.json. Licence CC BY-NC 4.0.